EUCTR2018-004278-91-SE进行中（未招募）1 期
A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETYAND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATEVACCINE IN ADULTS ?65 YEARS OF AGE WITH PRIOR PNEUMOCOCCALVACCINATIO
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 875
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Evidence of a personally signed and dated informed consent document (ICD) indicating that the subject has been informed of all pertinent aspects of the study.
- •2. Willing and able to comply with scheduled visits, treatment plan, and other study procedures.
- •3. Expected to be available for the duration of the study and can be contacted by telephone during study participation.
- •4. Male or female adults >/=65 years of age.
- •5. Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
- •6. Female subject of nonchildbearing potential; male subject not able to father children; male subject who is able to father children and willing to use a highly effective method of contraception as outlined in this protocol until at least 28 days after the last dose of investigational product.
- •Note: Female subjects of nonchildbearing potential must meet the criteria described in the Woman of Childbearing Potential (WOCBP)
- •7. Male or female adults who meet 1 of the following:
- •a. Vaccination with PPSV23 >/=1 year and b. Vaccination with 13vPnC >/=6 months prior to vaccination in the study, and no prior PPSV23 vaccination (Cohort B).
- •c. Vaccination with 13vPnC followed by PPSV23 (PPSV23 vaccination >/=1 year prior to vaccination in the study) (Cohort C).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 875
排除标准
- •1. Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or subjects who are Pfizer employees, including their family members, directly involved in the conduct of the study.
- •2. Participation in other studies involving investigational drug(s), investigational vaccines, or investigational devices within 28 days prior to study entry and/or during study participation. Participation in purely observational studies is acceptable.
- •3. History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of 20vPnC, 13vPnC, or any other diphtheria toxoid?containing vaccine, or PPSV23.
- •4. Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator?s opinion, excludes the subject from participating in the study.
- •5. Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
- •6. History of microbiologically proven invasive disease caused by S pneumoniae.
- •7. Subjects who receive treatment with immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, or planned receipt through the last blood draw. If systemic corticosteroids have been administered short term (<14 days) for treatment of an acute illness, subjects should not be enrolled into the study until corticosteroid therapy has been discontinued for at least 28 days before investigational product administration. Inhaled/nebulized, intra-articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted.
- •8. Subjects with known or suspected immunodeficiency or other conditions associated with immunosuppression, including, but not limited to, immunoglobulin class/subclass deficiencies, generalized malignancy, human immunodeficiency virus (HIV) infection, leukemia, lymphoma, or organ or bone marrow transplant.
- •9. Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
- •10. Receipt of blood/plasma products or immunoglobulin, from 60 days before investigational product administration, or planned receipt through study participation.
研究者
相似试验
进行中（未招募）
不适用
A clinical study to test the safety, tolerability and immune response of a vaccine against pneumococcal bacteria, presented in a multidose vial given with other vaccines to healthy infants.MedDRA version: 17.1Level: PTClassification code 10061353Term: Pneumococcal infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2012-000482-21-Outside-EU/EEAPfizer Inc500
进行中（未招募）
1 期
A RANDOMISED, OPEN-LABEL PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF BEXAROTENE (TARGRETIN) CAPSULES COMBINED WITH PUVA, COMPARED TO PUVA TREATMENT ALONE IN PATIENTS WITH MYCOSIS FUNGOIDES.CUTANEOUS T CELL LYMPHOMA.EUCTR2004-003701-24-ITE.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER
进行中（未招募）
不适用
Trial of Aeroquin versus Tobramycin Inhalation Solution(TIS) in Stable Cystic Fibrosis PatientsPseudomonas aeruginosa infection in patients suffering from stable Cystic FibrosisMedDRA version: 14.1Level: PTClassification code 10011763Term: Cystic fibrosis lungSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 14.1Level: LLTClassification code 10021860Term: Infection pseudomonas aeruginosaSystem Organ Class: 10021881 - Infections and infestationsEUCTR2010-019634-26-IEMpex Pharmaceuticals, Inc.330
进行中（未招募）
1 期
Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) PatientsPseudomonas aeruginosa infection in patients suffering from stable Cystic FibrosisMedDRA version: 14.0 Level: PT Classification code 10011763 Term: Cystic fibrosis lung System Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 14.0 Level: LLT Classification code 10021860 Term: Infection pseudomonas aeruginosa System Organ Class: 10021881 - Infections and infestationsEUCTR2010-019634-26-GBMpex Pharmaceuticals, Inc.330
进行中（未招募）
1 期
A Phase 3, Open-Label, Randomized Trial to Evaluate the Safety and Efficacy ofMP-376 Inhalation Solution (Aeroquin™) versus Tobramycin Inhalation Solution(TIS) in Stable Cystic Fibrosis PatientsEUCTR2010-019634-26-FRMpex Pharmaceuticals, Inc.330